Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of botulinum toxin A treatment in children with dysfunctional voiding
NL-OMON23220Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in Dysfunctional voiding (DV), sponsored by Erasmus MC. Primary endpoint: Post-void residual urine volume. Planned start Aug 2014; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Dysfunctional voiding (DV)
Beyond the preview
Go deeper on NL-OMON23220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23220.